Filing Details

Accession Number:
0001209191-21-051910
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-17 17:00:33
Reporting Period:
2021-08-16
Accepted Time:
2021-08-17 17:00:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1490978 Schrodinger Inc. SDGR Pharmaceutical Preparations (2834) 954284541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797672 Karen Akinsanya C/O Schrodinger, Inc.,
120 West 45Th Street, 17Th Floor
New York NY 10036
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-16 20,181 $17.00 20,181 No 4 M Direct
Common Stock Acquisiton 2021-08-16 4,180 $4.34 24,361 No 4 M Direct
Common Stock Acquisiton 2021-08-16 13,377 $3.22 37,738 No 4 M Direct
Common Stock Disposition 2021-08-16 21,691 $57.43 16,047 No 4 S Direct
Common Stock Disposition 2021-08-16 16,047 $58.17 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-08-16 20,181 $0.00 20,181 $17.00
Common Stock Stock Option (right to buy) Disposition 2021-08-16 4,180 $0.00 4,180 $4.34
Common Stock Stock Option (right to buy) Disposition 2021-08-16 13,377 $0.00 13,377 $3.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
180,478 2030-02-05 No 4 M Direct
45,985 2028-11-29 No 4 M Direct
13,378 2028-08-03 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.905 to $58.86, inclusive.
  4. This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.
  5. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.
  6. The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022.